skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8838

An update on the use of Atripla® in the treatment of HIV in the United States

Review

(2113) Views  (1188) Full article downloads

Authors: Michael A Horberg, Daniel B Klein

Published Date June 2010 Volume 2010:2 Pages 135 - 140
DOI: http://dx.doi.org/10.2147/HIV.S6366

Michael A Horberg1, Daniel B Klein2

1HIV Interregional Initiative, Kaiser Permanente, Oakland, California, USA; 2Department of Infectious Diseases, Kaiser Permanente Hayward Medical Center, Hayward, California, USA

Abstract: Atripla® (Gilead Sciences Inc, Foster City, CA, USA and Bristol-Myers Squibb, New York City, NY, USA) is a coformulated single pill composed of efavirenz, emtricitabine, and tenofovir disoproxil, intended as a once-daily potent combination antiretroviral therapeutic agent. Its efficacy is equivalent to the 3 component drugs taken in a combination as single medications. The coformulated antiretroviral regimen can be quite effective in patients whose human immunodeficiency virus is sensitive to all 3 components of Atripla. However, women at risk of pregnancy, already pregnant, or nursing mothers should not take Atripla, due to the teratogenic potential of the efavirenz moiety. Adverse effects are similar to those seen with the constituent medications, including potential central nervous system effects and renal toxicity. Since its US Food and Drug administration approval, prescriptions for Atripla have increased steadily.

Keywords: tenofovir, efavirenz, emtricitabine, antiretroviral therapy








Readers of this article also read:

“One pill, once daily”: what clinicians need to know about Atripla™
Atripla™ – HIV therapy in one pill
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Exacerbation rate, health status and mortality in COPD – a review of potential interventions
The prevalence of human immunodeficiency virus infection among TB patients in Port Harcourt Nigeria
Novel strategies in the use of lopinavir/ritonavir for the treatment of HIV infection in children
Retinal nerve fiber layer thickness in recovered and persistent amblyopia
Antiretroviral therapy initiated soon after HIV diagnosis as standard care: potential to save lives?
The relationship between deliberate self-harm behavior, body dissatisfaction, and suicide in adolescents: current concepts
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy